UroGen Pharma (URGN) Research & Development (2017 - 2026)

UroGen Pharma (URGN) has reported Research & Development for 10 consecutive years, with $15.6 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development fell 21.51% year-over-year to $15.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.8 million (up 2.13% YoY) and the FY2025 annual result came in at $67.1 million, up 17.43% from the prior year.
• Research & Development improved to $15.6 million in Q1 2026 per URGN's latest filing, from $14.3 million in the prior quarter.
• Over the last five years, Research & Development for URGN reached as high as $19.9 million in Q1 2025 and fell as low as $10.2 million in Q3 2023.
• A 5-year average of $14.0 million and a median of $14.0 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development dropped 21.93% — and 2024, when it soared 32.96%.
• Year by year, Research & Development stood at $14.5 million in 2022, then slipped by 21.93% to $11.3 million in 2023, then jumped by 31.78% to $14.9 million in 2024, then declined by 3.89% to $14.3 million in 2025, then increased by 8.96% to $15.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.6 million, $14.3 million, and $14.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.